Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial

  1. Pal, S.K.
  2. Puente, J.
  3. Heng, D.Y.C.
  4. Glen, H.
  5. Koralewski, P.
  6. Stroyakovskiy, D.
  7. Alekseev, B.
  8. Parnis, F.
  9. Castellano, D.
  10. Ciuleanu, T.
  11. Lee, J.L.
  12. Sunela, K.
  13. O'Hara, K.
  14. Binder, T.A.
  15. Peng, L.
  16. Smith, A.D.
  17. Rha, S.Y.
Aldizkaria:
European Urology

ISSN: 1873-7560,  0302-2838

Argitalpen urtea: 2022

Alea: 82

Zenbakia: 3

Orrialdeak: 283-292

Mota: Artikulua

DOI: 10.1016/J.EURURO.2021.12.024 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus